RecruitingPhase 2Phase 3NCT03818334

Post Transplant Cyclophosphamide in Matched Unrelated Donor Stem Cell Transplantation for Hematological Malignancies

Use of Post Transplant Cyclophosphamide as Graft Versus Host Disease Prophylaxis in Matched Unrelated Donor Stem Cell Transplantation for Hematological Malignancies, a Prospective Randomized Controlled Trial

Sponsor

Hospital Israelita Albert Einstein

Enrollment

50 participants

Start Date

Nov 6, 2018

Study Type

INTERVENTIONAL

Conditions

Graft-Versus-Host Disease Bone Marrow Transplant Complications Immunologic Suppression Infection Viral Engraft Failure

Summary

This study aims to evaluate the clinical efficacy of cyclophosphamide in patients receiving a bone marrow graft from a matched unrelated donor in overall survival, progression free survival and cumulative incidence of acute and chronic GvHD. Thirty patients will receive cyclophosphamide while twenty patients will receive antihuman T-lymphocyte immune globulin (ATG).

Eligibility

Min Age: 1 YearMax Age: 75 Years

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying a drug called ATG and a drug called Cyclophosphamide for people with bone marrow transplant complications, engraft failure, and other related conditions. The study is currently recruiting participants at 1 location. People eligible for this study include aged 1 Year to 75 Years.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.